| Autor: |
Iulita, M. Florencia, Ferrari, Alberto, Harms, Robbert, Quevenco, Frances‐Catherine, Sánchez‐Benavides, Gonzalo, Minguillón, Carolina, Balasa, Mircea, Bügler, Maximilian, Santuccione, Antonella, Tarnanas, Ioannis |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2023 Supplement 18, Vol. 19, p1-4, 4p |
| Abstrakt: |
Background: One of the major challenges in Alzheimer's disease (AD) is the identification of individuals at the earliest stages, who might benefit from disease‐modifying therapies. People presenting with clinical syndromes such as subjective cognitive decline (SCD), or mild cognitive impairment (MCI) harboring AD pathology are at high risk of cognitive worsening over time. Digital biomarkers could enable early, accurate and accessible diagnoses, and thus, streamline the patient journey to specialized care. Methods: We included 102 participants from the β‐AARC cohort, established at the Barcelonaβeta Brain Research Center (BBRC), consisting of individuals seeking medical advice on their cognitive performance, mostly in primary care settings. Participants were classified as SCD (n = 94; age 66.4 [6.2] years; MMSE score 28.5 [1.3]) or MCI (n = 8; age 70.1 [4.6] years; MMSE score 26.3 [2.8]) after objective cognitive testing (Table 1). All had core CSF biomarkers (Aβ42/40, ptau‐181, t‐tau) determined with the Lumipulse automated platform (Fujirebio). Participants completed a digital cognitive assessment with Altoida's research medical device. The device evaluates cognitive and functional impairment based on motoric and augmented reality tasks that simulate activities of daily living. These tasks evaluate multi‐modal features, including micro‐movements, micro‐errors, speed, reaction times, or navigation trajectories, which are used to train specific machine‐learning models, termed Digital Neuro Signature (DNS). The DNS‐MCI algorithm identifies cognitively normal individuals from those presenting with cognitive impairment. We compared DNS‐MCI scores across study groups and explored correlations with core AD biomarkers. Result: DNS‐MCI scores were significantly lower in individuals presenting with MCI compared with SCD (p<0.05; Figure 1A). Participants who were Aβ+ based on the Aβ42/40 ratio (cut‐off ≤0.062) showed significantly lower DNS‐MCI scores compared with those who were Aβ‐ (p<0.001 for the whole sample; and p<0.05 for the SCD subsample (Figure 1B)). DNS‐MCI scores showed significant modest correlations with Aβ42/40, ptau‐181/Aβ42, ptau‐181 and t‐tau biomarkers (Figure 2). Conclusion: Digital biomarkers identified differences in cognitive performance between MCI/SCD and Aβ+/Aβ‐ participants in a cohort with cognitive complaints seeking medical advice. DNS‐MCI scores correlated with core CSF AD biomarkers. This work has received support from the Alzheimer's Drug Discovery Foundation (grant #GDADB‐201906‐2018897) to Ioannis Tarnanas. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
